YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells

Overview

Journal iScience

Publisher Cell Press

Date 2018 Nov 15

PMID 30428369

Citations 31

Authors

Mumtaz Y Balkhi

Gabor Wittmann

Fang Xiong

Richard P Junghans

Affiliations

Soon will be listed here.

Abstract

T cells infiltrate affected organs in chronic infections and malignancy, but they may fail to eradicate virus-infected cells or tumor because of exhaustion. This report describes a Yin Yang-1 (YY1)-centered mechanism for diverse components that have been correlated with exhaustion. Utilizing an in vitro reconstruction of chronic T cell activation, YY1 is shown to positively regulate the checkpoint receptors PD1, Lag3, and Tim3 and to negatively regulate the type I cytokines interleukin-2 (IL-2) (in collaboration with Ezh2 histone methyltransferase) and interferon gamma (IFN-?). Other tests suggest that IL-2 failure drives a large component of cytotoxic functional decline rather than solely checkpoint receptor-ligand interactions that have been the focus of current anti-exhaustion therapies. Clinical evaluations confirm elevated YY1 and Ezh2 in melanoma tumor-infiltrating lymphocytes and in PD1+ T cells in patients with HIV. Exhaustion is revealed to be an active process as the culmination of repetitive two-signal stimulation in a feedback loop via CD3/CD28?p38MAPK/JNK?YY1? exhaustion.

Citing Articles

Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.

Goleij P, Heidari M, Tabari M, Hadipour M, Rezaee A, Javan A Funct Integr Genomics. 2025; 25(1):53.

PMID: 40048009 DOI: 10.1007/s10142-025-01563-8.

Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells.

Emerson D, Merriman E, Yachi P Front Immunol. 2025; 16:1534462.

PMID: 39981237 PMC: 11840260. DOI: 10.3389/fimmu.2025.1534462.

Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect.

Hsu C, Mohammed A, Hjazi A, Uthirapathy S, Renuka J, Singh A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39960560 DOI: 10.1007/s00210-025-03883-9.

Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis.

Cheng R, Tang X, Zhao Q, Wang Y, Chen W, Wang G Research (Wash D C). 2025; 8():0578.

PMID: 39810853 PMC: 11731779. DOI: 10.34133/research.0578.

ETV7 limits the antiviral and antitumor efficacy of CD8 T cells by diverting their fate toward exhaustion.

Cheng J, Xiao Y, Peng T, Zhang Z, Qin Y, Wang Y Nat Cancer. 2025; 6(2):338-356.

PMID: 39805956 DOI: 10.1038/s43018-024-00892-0.

References

Emtage P, Lo A, Gomes E, Liu D, Gonzalo-Daganzo R, Junghans R . Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res. 2008; 14(24):8112-22. PMC: 2659496. DOI: 10.1158/1078-0432.CCR-07-4910. View

Martins G, Cimmino L, Liao J, Magnusdottir E, Calame K . Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med. 2008; 205(9):1959-65. PMC: 2526191. DOI: 10.1084/jem.20080526. View

Atchison M . Function of YY1 in Long-Distance DNA Interactions. Front Immunol. 2014; 5:45. PMC: 3918653. DOI: 10.3389/fimmu.2014.00045. View

Nguyen L, Ohashi P . Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2014; 15(1):45-56. DOI: 10.1038/nri3790. View

Day C, Kaufmann D, Kiepiela P, Brown J, Moodley E, Reddy S . PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443(7109):350-4. DOI: 10.1038/nature05115. View

Appleman L, Boussiotis V . T cell anergy and costimulation. Immunol Rev. 2003; 192:161-80. DOI: 10.1034/j.1600-065x.2003.00009.x. View

Liao W, Lin J, Leonard W . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013; 38(1):13-25. PMC: 3610532. DOI: 10.1016/j.immuni.2013.01.004. View

Raingeaud J, Gupta S, Rogers J, Dickens M, Han J, Ulevitch R . Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995; 270(13):7420-6. DOI: 10.1074/jbc.270.13.7420. View

Atkins M, Kunkel L, Sznol M, Rosenberg S . High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000; 6 Suppl 1:S11-4. View

10.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

11.

Leavy O . Autoimmunity: Benefits of exhaustion. Nat Rev Immunol. 2015; 15(8):468. DOI: 10.1038/nri3890. View

12.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

13.

Conze D, Krahl T, Kennedy N, Weiss L, Lumsden J, Hess P . c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J Exp Med. 2002; 195(7):811-23. PMC: 2193724. DOI: 10.1084/jem.20011508. View

14.

Ye J, Cippitelli M, Dorman L, Ortaldo J, Young H . The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Mol Cell Biol. 1996; 16(9):4744-53. PMC: 231475. DOI: 10.1128/MCB.16.9.4744. View

15.

Rosenberg S, Mule J, Spiess P, Reichert C, Schwarz S . Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985; 161(5):1169-88. PMC: 2187617. DOI: 10.1084/jem.161.5.1169. View

16.

Blattman J, Grayson J, Wherry E, Kaech S, Smith K, Ahmed R . Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003; 9(5):540-7. DOI: 10.1038/nm866. View

17.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

18.

Mognol G, Spreafico R, Wong V, Scott-Browne J, Togher S, Hoffmann A . Exhaustion-associated regulatory regions in CD8 tumor-infiltrating T cells. Proc Natl Acad Sci U S A. 2017; 114(13):E2776-E2785. PMC: 5380094. DOI: 10.1073/pnas.1620498114. View

19.

Balkhi M, Ma Q, Ahmad S, Junghans R . T cell exhaustion and Interleukin 2 downregulation. Cytokine. 2014; 71(2):339-47. DOI: 10.1016/j.cyto.2014.11.024. View

20.

West E, Jin H, Rasheed A, Penaloza-MacMaster P, Ha S, Tan W . PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013; 123(6):2604-15. PMC: 3668811. DOI: 10.1172/JCI67008. View